Professional Seasonal Analysis for Trading

Jasper Therapeutics, Inc. - Class A Common Stock (JSPR)

Seasonality Analysis

Stocks 7 Years Analyzed

Jasper Therapeutics, Inc. - Class A Common Stock Annual Seasonality Statistics

-55.89%
Avg Annual Return
35.3%
Avg Monthly Win Rate
3/12
Positive Months
7
Years Analyzed

Jasper Therapeutics, Inc. - Class A Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -13.91%
29%
Very Weak
February BEST 6.93%
43%
Weak
March -4.92%
29%
Very Weak
April 1.41%
57%
Moderate
May 2.05%
50%
Weak
June -9.34%
50%
Weak
July -10.86%
17%
Very Weak
August -0.30%
33%
Very Weak
September WORST -18.38%
17%
Very Weak
October -0.60%
17%
Very Weak
November -7.60%
33%
Very Weak
December -0.38%
50%
Weak

Jasper Therapeutics, Inc. - Class A Common Stock 2026 vs Historical Pattern

Current Position
25.83
Historical Avg Position
38.81
Deviation
-12.98
Performance
Significantly Below Average

Jasper Therapeutics, Inc. - Class A Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for JSPR with overlay patterns, custom date ranges, and more.

Create Free Account

Jasper Therapeutics, Inc. - Class A Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Jasper Therapeutics, Inc. - Class A Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for JSPR across multiple timeframes.

Create Free Account

About Jasper Therapeutics, Inc. - Class A Common Stock (JSPR) Seasonality

Jasper Therapeutics, Inc. - Class A Common Stock (JSPR) has been analyzed using 7 years of historical data to identify seasonal patterns. Classified under Stocks, Jasper Therapeutics, Inc. - Class A Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Jasper Therapeutics, Inc. - Class A Common Stock is historically February, with an average return of 6.93% and a win rate of 43%. Conversely, September tends to be the weakest month, averaging -18.38% return.

Looking at the full calendar year, Jasper Therapeutics, Inc. - Class A Common Stock has an average annual return of -55.89% with an overall monthly win rate of 35.3%. Out of 12 months, 3 typically show positive average returns.

The seasonal pattern for Jasper Therapeutics, Inc. - Class A Common Stock has a consistency score of 51.5 (Fair), based on 7 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Jasper Therapeutics, Inc. - Class A Common Stock Seasonality FAQ

What is the best month to buy Jasper Therapeutics, Inc. - Class A Common Stock (JSPR)?

Historically, February has been the best month for Jasper Therapeutics, Inc. - Class A Common Stock, with an average return of 6.93% and a win rate of 43%. However, past performance does not guarantee future results.

What is the worst month for Jasper Therapeutics, Inc. - Class A Common Stock (JSPR)?

Based on historical data, September has been the weakest month for Jasper Therapeutics, Inc. - Class A Common Stock, with an average return of -18.38%. This is a historical observation and does not guarantee future results.

How reliable is JSPR seasonality data?

The seasonality analysis for Jasper Therapeutics, Inc. - Class A Common Stock is based on 7 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Jasper Therapeutics, Inc. - Class A Common Stock seasonality in my trading?

Use Jasper Therapeutics, Inc. - Class A Common Stock (JSPR) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.